Autologous fat-derived vs umbilical cord-derived stem cells: sources, Japan’s registration classes, and how to choose

Mesenchymal stem cells (MSCs) can be isolated from multiple tissues such as fat, bone marrow, and umbilical cord. Regardless of source, labs identify them by a common minimal set of criteria: adherence to plastic, specific surface markers, and tri-lineage differentiation into fat, bone, and cartilage under defined conditions. Thus “fat-derived stem cells” and “umbilical cord-derived stem cells” refer to the same category of cells from different sources; they are not iPS cells or ES cells.

Different sources mean cell properties are not identical, such as proliferation rate in culture and secreted factors. But note: for most diseases, high-quality clinical studies directly comparing the two sources are still lacking. Much of what you see online about “which works better” does not come from such head-to-head comparisons.

Below is a comparison along the most common consultation questions. Follow the institution’s written information for specifics.

Autologous cells come from you, so there is no donor and none of the immune issues that someone else’s cells can raise. But the cells’ condition reflects your own: studies suggest that factors such as age, obesity, and diabetes may affect the proliferation and function of fat-derived stem cells, so even with the same culture method, results vary from person to person. Also, liposuction itself is a minor medical procedure; if you are taking anticoagulants or your health is unstable, have a doctor assess you first.

Umbilical cord-derived stem cells come from umbilical cords that are usually discarded after birth. The tissue itself is “young,” and many studies observe faster proliferation in culture; they are also convenient for advance, batch-wise preparation and testing. But they are someone else’s cells: you need to see how donors are screened, what infection testing is done, and whether each batch is traceable. The immunogenicity of mesenchymal stem cells is considered relatively low, but “relatively low” does not mean “none,” and post-infusion observation is equally important.

Both promotional lines need an extra layer of thought: “your own cells have no rejection” does not mean no risk; there are risks in both culture and infusion. “Cord cells are younger” does not mean they are more effective for your condition; that depends on clinical evidence for the specific disease.

Japan’s Act on the Safety of Regenerative Medicine classifies regenerative medicine into three risk classes. Under the official classification flow, using “cells from someone other than the treatment recipient” (i.e., someone else’s cells), along with iPS cells, ES cells, gene-modified cells, and animal cells, falls under Class I; using your own somatic stem cells that have been cultured generally falls under Class II. Cord-derived cells are someone else’s cells, so they are Class I.

The procedures for the two classes differ greatly. Class II plans can start provision upon submission after review by a Specially Certified Committee for Regenerative Medicine; Class I also requires that committee’s review, but after submission there is an additional 90-day period during which provision cannot start, and during that time the MHLW seeks the opinion of the Health Sciences Council and may require plan changes if standards are not met. In the official public list, Class I plans are far fewer than Class II.

For this reason, in Japanese clinics, self-pay stem cell treatments currently focus on autologous cells, most commonly fat-derived (bone marrow-derived also exists), registered as Class II. Since January 2026 the MHLW has been discussing a further revision of the Act, including a review of the risk classification; until the Act is formally amended, the current classification applies.

Many “umbilical cord” offerings on the market do not use cells but rather the conditioned medium (culture supernatant) obtained when culturing cord-derived stem cells, or exosomes extracted from it. These do not contain cells. As of October 2026, exosomes and conditioned medium are not yet covered by the Act on the Safety of Regenerative Medicine, so there are no provision plans to look up; the MHLW is discussing how to regulate them.

So when you hear “we use umbilical cord stem cells,” first ask: are they live cells, or conditioned medium or exosomes? The legal framework differs, and what you actually receive is entirely different. For exosomes, see this site’s exosome guide.

In China, cell therapy products must be approved as drugs by the National Medical Products Administration. Amimestrocel injection, conditionally approved in January 2025, is a human umbilical cord-derived mesenchymal stem cell preparation for certain cases of steroid-refractory acute graft-versus-host disease. Japan approved a similar product in 2015 using mesenchymal stem cells from healthy adult bone marrow, with the same indication of acute graft-versus-host disease. These are products for specific diseases, regulated as drugs, and are not the same as self-pay treatments you can choose freely.

Outside of drugs, stem cell technologies in China are mainly conducted as clinical research. The Regulations on Clinical Research and Clinical Translational Application of New Biomedical Technologies, effective May 1, 2026, continue the principle that clinical research may not charge subjects. So when comparing “umbilical cord-derived stem cells in China” with “autologous fat-derived stem cells in Japan,” you are actually comparing two different legal pathways, not just two cell sources.

My suggestion: don’t start by asking “are fat-derived or cord-derived better.” The order should be: first let a doctor review your records and tests to decide whether stem cells are appropriate; then consider how many trips and how much time in Japan you can accept; finally, see whether the institution can provide under a compliant plan and clearly explain the cell testing data. During consultation, you can directly ask:

Our partner Ginza YR Clinic has regenerative medicine provision plans registered only as Class II and Class III; its stem cell treatments use the patient’s own fat-derived stem cells, cultured in an in-house cell processing center (CPC). Its umbilical cord-related offering is exosomes, which contain no cells. For the 9 plan numbers and how to verify them, see this site’s “What regenerative medicine registrations does Ginza YR Clinic have” (this site has a partnership with that clinic; see About Us).